https://www.biotechdaily.com.au/index.php

Biotech Daily Home

Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Base-rate subscriptions are $A1450 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

 

Download subscription form here
 

 

 

Latest News !
 

Avita Raises $120m at 59¢

FDA Okays Redhill Talicia (Sydney's Heliconda) For H. Pylori

Botanix Falls 48% As Cannabinoid BTX1503 Misses Acne Endpoint

Clinuvel Up 63% On FDA Scenesse For EPP Approval

Dr Boreham's Crucible: Painchek

Actinogen: 'Xanamem Improves Cognition In Healthy Volunteers' - Up 467%

Antisense Jumps 100% On ATL1102 'Positive Drug Effect For DMD'

Opthea Jumps 160% on OPT-302 Wet AMD Result

Bionomics BNC210 Fails 2nd Phase II Trial (Agitation)

Orthocell Up 377% On 4-Patient Celgro Nerve Regeneration

Actinogen: 'Xanamem Fails Alzheimer's Endpoints'; Falls 71%

 

  


 

12-Month BDI-40 Up 104%, ASX200 14%,
Big Caps 37%, Cannabis Crash
 

 

November 1, 2019

 

The Biotech Daily Top 40 Index (BDI-40) has leapt 103.5 percent in the 12 months to October 31, 2019, the greatest leap forward in the 13 years of the index.
 
The benchmark ASX200 improved 14.3 percent for the 12-months, but the collective value of the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) rose a very significant 36.5 percent to $159,000 million.
 
The Nasdaq Biotechnology Index (NBI) finally showed signs of recovery, up 7.7 percent for the month of October and 2.9 percent for the year to October 31.
 
For the month of October, the ASX200 fell 0.4 percent, the BDI-40 was up 3.4 percent; and the Big Caps rose 8.5 percent.
 
In October, the market cap of The Magic Pudding*, trading as CSL Limited, was up a further $10.1 billion or 9.6 percent to a record $116,204 million, followed by Resmed up 7.3 percent to a record $30,565 million and Cochlear up 1.7 percent to a record $12,231 million.
 
While Mesoblast has slipped from the BDI-40 Billion Dollar Club, Nanosonics has joined the Two Billion Dollar Club.
 
Twenty-four of the BDI-40 stocks were up, with 13 up by more than 10 percent, while 12 companies fell, with eight down by more than 10 percent. Four were unchanged.
 
From a low base, Actinogen recovered 270 percent to $27 million on good trial data, LBT was up 92 percent to $48 million on its first European sale, followed by Orthocell (61.3%), Oncosil (61.0%), Antisense (27.3%), Clinuvel (23.7%), Immutep (22.5%), Compumedics (16.5%), Medical Developments (16.0%) and Neuren (13.4%).
 
Kazia led the falls down 22.9 percent to $27 million followed by Impedimed (22.0%), Osprey (20.0%), Cynata (18.8%), Next Science (17.4%), Patrys (13.0%), Universal Biosensors (11.4%) and Mesoblast (10.2%).
 
The 18 companies in Cannabis Corner tumbled 29.4 percent in October, down 42.3 percent from the July 31 high of $1,913 million to $1,103 million today. Thirteen companies fell, three were unchanged and just Palla Pharma (Tasmanian Poppy Industries) and the re-born Australian Primary Hemp (Alchemia) improved.
 
Botanix led the falls, down $135 million or 56.0 percent on its failed acne trial, with investors working out that “inflammatory lesions” meant whitehead pimples, and the synthetic cannabinoid compound was no better than placebo. Althea lost 48.3 percent followed by Creso (46.6%), Cann Group (35.9%), Bod (32.5%), Cann Global (26.7%), Elixinol (25.7%), Zelda (21.9%) and Auscann (21.6%).
 
In the US, Eyepoint (Psivida) was up 22.5 percent to $348 million, Israel’s Redhill with Australian assets was up 15.9 percent to $343 million and Queensland’s Protagonist was up 9.6 percent to $512 million.
 

 

 

BDI-40 v S&P ASX200 Jun 30, 2006 to Oct 31, 2019 
 
3-Year Big Caps (Cochlear, CSL, Resmed) to Oct 31, 2019


BDI-40 ($m) v S&P ASX200 – Year to Oct 31, 2019 (current, raw data)
 

 

 

 

 Click here for Biotech Daily's archive

 

   

Biotech Daily Top 40 With Market Capitalization At Oct 31, 2019

 

* Biotech Daily editor, David Langsam, owns shares in Acrux, Alterity, Amplia, Cynata, Mesoblast
   Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: http://www.australianethical.com.au/who-we-invest-in